Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.22 USD | -5.13% | -20.14% | +73.44% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 145M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -46M | EV / Sales 2024 * | - |
Net cash position 2024 * | 94.2M | Net cash position 2025 * | 50.8M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.37
x | P/E ratio 2025 * |
-3.64
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.25% |
Latest transcript on Regulus Therapeutics Inc.
1 day | -5.13% | ||
1 week | -20.14% | ||
Current month | -22.92% | ||
1 month | -5.93% | ||
3 months | +81.97% | ||
6 months | +72.09% | ||
Current year | +73.44% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Hagan
CEO | Chief Executive Officer | 55 | 16-01-03 |
Preston Klassen
PSD | President | 55 | 23-06-21 |
Crispina Calsada
DFI | Director of Finance/CFO | 54 | 19-08-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 17-05-31 |
David Baltimore
BRD | Director/Board Member | 86 | 08-12-31 |
Director/Board Member | 75 | 13-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 2.22 | -5.13% | 202,895 |
24-04-17 | 2.34 | -8.59% | 295,342 |
24-04-16 | 2.56 | -7.91% | 455,858 |
24-04-15 | 2.78 | -0.71% | 315,039 |
24-04-12 | 2.8 | +0.72% | 343,860 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+73.44% | 145M | |
-3.30% | 102B | |
+1.79% | 96.07B | |
-0.44% | 21.66B | |
-18.35% | 20.77B | |
-7.45% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B |
- Stock Market
- Equities
- RGLS Stock